Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 210 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Athyros, Vasilios G  [Clear All Filters]
2013
Koumaras, C., Katsiki N., Athyros V. G., & Karagiannis A. (2013).  Metabolic syndrome and arterial stiffness: the past, the present and the future.. J Cardiovasc Med (Hagerstown). 14(10), 687-9.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Nonalcoholic fatty liver disease and severity of cardiovascular disease manifestations.. Angiology. 64(8), 572-5.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Prevalence and clinical outcome of polyvascular atherosclerotic disease in patients undergoing coronary intervention.. Circ J. 77(5), 1348.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2013).  Statins and nonalcoholic fatty liver disease: a bright future?. Expert Opin Investig Drugs. 22(9), 1089-93.
Anagnostis, P., Athyros V. G., Kita M., & Karagiannis A. (2013).  Is there any association between adiponectin gene polymorphisms and cardiovascular disease?. Angiology. 64(4), 253-6.
2012
Athyros, V. G., Gossios T. D., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings.. Arch Med Sci. 8(1), 6-10.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?. Curr Vasc Pharmacol. 10(3), 374-7.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance.. J Clin Lipidol. 6(1), 93.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Fibrinogen, hematocrit, and platelets in mild kidney dysfunction and the role of uric acid: an Italian male population study.. Clin Appl Thromb Hemost. 18(1), 113-4.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Lipid lowering agents and the endothelium: an update after 4 years.. Curr Vasc Pharmacol. 10(1), 33-41.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome.. Expert Opin Pharmacother. 13(2), 287-8; author reply 289-90.
Kostapanos, M. S., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease.. Dig Dis Sci. 57(4), 1109.
Athyros, V. G., Karagiannis A., Katsiki N., & Mikhailidis D. P. (2012).  Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity.. Am J Cardiol. 110(5), 763.
Athyros, V. G., Karagiannis A., Katsiki N., & Mikhailidis D. P. (2012).  Response to 'Mildly decreased glomerular filtration rate is associated with poor coronary heart disease outcome'.. Clin Cardiol. 35(5), 315; author reply 316-7.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Should raising high-density lipoprotein cholesterol be a matter of debate?. J Cardiovasc Med (Hagerstown). 13(4), 254-9.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial.. J Hepatol. 57(2), 476.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Stage of chronic kidney disease and severity of coronary heart disease manifestation.. Expert Opin Pharmacother. 13(4), 457-60.
Kostapanos, M. S., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Therapeutic options for statin-intolerant patients.. Curr Med Res Opin. 28(3), 345-9.
Mitsiou, E. K., Athyros V. G., Karagiannis A., & Mikhailidis D. I. (2012).  Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes?. Open Cardiovasc Med J. 6, 28-32.
Katsiki, N., Koumaras C., Athyros V. G., & Karagiannis A. (2012).  Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk.. Angiology. 63(1), 9-11.
2011
Katsiki, N., Mikhailidis D. P., Athyros V. G., & Karagiannis A. (2011).  Alanine aminotransferase is associated with metabolic syndrome independently of insulin resistance.. Circ J. 75(8), 2027; author reply 2028.
Stavrinou, E., Koumaras C., Gossios T. D., Tziomalos K., Athyros V. G., & Karagiannis A. (2011).  Atherosclerotic renal artery stenosis: an update on diagnosis and management.. Curr Vasc Pharmacol. 9(4), 465-70.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Current treatment for nonalcoholic fatty liver disease.. Expert Opin Pharmacother. 12(13), 2141-2; author reply 2142.
Katsiki, N., Athyros V. G., & Mikhailidis D. P. (2011).  The DEFINE study: a bright future for CETP inhibitors?. Expert Opin Investig Drugs. 20(3), 311-4.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2011).  Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment.. Open Cardiovasc Med J. 5, 24-34.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές